Understanding AOD 9604: The Fat-Burning Peptide

Are you looking for effective fat loss strategies to burn off that extra weight? Well, you’re not alone. Research into using peptides like AOD 9604 for weight management is booming.

Researchers want to discover its potential for treating obesity, repairing cartilage, and improving muscle recovery. It could reduce fat and prevent weight gain without negatively impacting insulin levels.

By understanding how AOD 9604 works and the benefits it could offer, you might be able to develop a more effective weight loss plan. You may even find other potential advantages that could help you.

What is AOD 9604?

The human body naturally produces different peptides to serve various internal functions. They consist of the building blocks of proteins: amino acids.

AOD 9604 is a peptide synthesized from the modified human growth hormone (HGH) fragment 177–191. Your pituitary gland releases HGH to help you grow as a child and maintains your body structure as an adult. It also affects your metabolism throughout your life.

While HGH boosts your insulin-like growth factor-1 (IGF-1), adjusting your blood sugar levels to burn fat, AOD 9604 doesn’t. Instead, it helps your body break down fat and prevents it from creating more without stimulating tissue or muscle growth.

This fat-burning peptide was initially developed as an anti-obesity drug (AOD). Its structure and function are similar to HGH. It also helps with body fat reduction and fat metabolism regulation, so it may be effective for weight management.

How does AOD 9604 work?

AOD 9604 triggers lipolysis (the breakdown of lipids, like fats), which affects adipose tissue (body fat). It can also reduce fat within your body.

A study on obese Zucker rats showed a reduction in body weight gain by over 50% in 19 days using this peptide. While it mimics HGH by stimulating the pituitary gland and speeding up the metabolism, it doesn’t affect insulin sensitivity.

These findings highlight the peptide’s potential to help with fat reduction in humans. It may also offer this advantage without the adverse effects associated with insulin-altering peptides.

AOD 9604 releases fatty tissue while preventing more from growing (lipogenesis). Once it effectively regulates your metabolism, your body’s fat loss rate speeds up.

Benefits of AOD 9604

A study on 300 obese patients revealed several potential benefits of AOD 9604. The researchers split the participants into six groups, administering a different dose per batch.

The group receiving 1 mg doses over 12 weeks showed the most significant results. They lost an average of 2.8 kgs (6.1 lbs) at a consistent rate throughout the treatment. This trend presents encouraging prospects for long-term use.

This clinical trial, along with another experiment on mice also revealed several other benefits to participants using AOD 9604.

Here are some of the advantages it offers:

• Reduction of impaired glucose tolerance: Unlike HGH and other weight-loss peptides, AOD 9604 has no adverse effects on your insulin levels. That means it doesn’t increase your risk of developing diabetes.
• Stimulates lipolysis and inhibits lipogenesis: AOD 9604 helps break down fat in fat cells and prevents further fat accumulation from non-fat food converting into body fat.
• Improved cholesterol profiles: A more balanced cholesterol profile helps you regulate insulin without suppressing your appetite. It also makes it easier for your body to process sugars and fats.
• Increases fat oxidation: AOD 9604 helps you burn fat instead of sugar when you exercise. That means you get a steady energy source, improving your endurance and fat loss.
• Boosts energy expenditure: The more energy you expend, the more calories you burn, allowing you to reach a caloric deficit. It also improves calorie burning at rest, making weight management easier.
• Muscle recovery: The AOD 9604 peptide promotes fat metabolism and could enhance energy levels. These effects may lead to better performance and faster recovery times. Pairing it with other peptides, like BPC-157, can boost muscle repair and regeneration.
• Joint health improvement: AOD 9604 could boost cartilage repair if used with BPC-157. Its joint healing potential may make it useful in treating conditions like osteoarthritis.

Current research and clinical studies

AOD 9604 may help with weight loss and fat gain prevention without influencing insulin or growth. It demonstrated these benefits in two studies: one on mice and the other on humans.

This form of peptide therapy is shown to trigger lipolysis and inhibit lipogenesis, improving metabolism and burning fat. It achieves this without increasing blood sugar levels or growth, reducing the risk of diabetes.

Alternate and ongoing studies

Research on AOD 9604, also called LAT8881, is changing direction from its focus on weight loss. It’s moving towards other advantages, like cartilage regeneration, influenza A virus (IVA) resistance, and neuropathic pain.

• A study on white rabbits showed that intra-articular injections in the knee improved cartilage regeneration. It promoted tissue repair and reduced damage caused by inflammation related to osteoarthritis.
• Another experiment found that AOD 9604 enhanced cell viability and improved influenza resistance in mice postinfection.
• An ongoing trial includes research on its potential to treat indications of neuropathic pain, like migraines. Each phase will investigate LAT8881’s potential to treat osteoarthritis and other chronic diseases.

Regulatory status

The FDA has three categories for bulk drug substances. The first covers those under evaluation, the second raises significant safety concerns, and the third are those nominated without adequate support.

AOD 9604 was previously under category two, but the FDA removed it after nominators withdrew their nominations. It gained its approval for research and experimental development (R&D) applications in compounded medications.

The FDA didn’t approve it as a standalone weight loss or obesity drug. The World Anti-Doping Agency (WADA) banned it because of its potential as a performance-enhancing drug.

Origins: The HGH Fragment 176–191

The story of AOD-9604’s origin begins with human growth hormone itself. HGH is a 191-amino-acid protein with diverse effects, one of which is promoting fat utilization. Scientists discovered that the fat-reducing activity of HGH could be traced to a specific region at the end of the hormone’s amino acid chain (residues 176–191). By isolating this fragment, researchers hoped to create a compound that triggers fat loss without the other effects of HGH (such as muscle/bone growth or blood sugar changes). AOD-9604 is essentially a modified version of this HGH fragment 176–191 – it includes a minor modification (a tyrosine substitution at one end) to enhance stability and activity. This modification does not change the fragment’s core function but helps it behave more like a standalone fat-burning agent.

The development of AOD-9604 was spearheaded by an Australian biopharmaceutical company (Metabolic Pharmaceuticals Ltd.) in the early 2000s​. Backed by significant investment and research, six human clinical trials were conducted between 2001 and 2007 to evaluate this peptide’s efficacy and safety in weight management. The goal was to create an “Advanced Obesity Drug” that could be taken (potentially even orally) to reduce body fat in obese individuals. In fact, AOD-9604 was tested as an oral peptide pill in some trials, making it unique among many research peptides which often require injection.

Through these efforts, AOD-9604 earned a reputation as the “lipolytic fragment” of HGH – meaning it can break down fat. Early laboratory studies confirmed that this fragment indeed stimulated the release of fat from adipose (fat) cells. By 2005, hundreds of trial participants had been dosed with AOD-9604, and researchers had gathered substantial data on its effects. Although it ultimately did not become a commercial pharmaceutical, AOD-9604’s origin as an HGH fragment solidified its place as a valuable tool for scientists studying fat metabolism.

Scientific Studies and Results

AOD-9604 has been put through multiple studies to evaluate its efficacy in promoting fat loss. Below is a summary of key findings from preclinical and clinical research on this peptide:

• Animal Studies: Early experiments in obese animal models demonstrated that AOD-9604 could significantly reduce body fat. In obese mice, chronic administration of AOD-9604 enhanced fat breakdown, leading to weight loss. Notably, mice genetically engineered without beta-3 adrenergic receptors showed no fat loss response, indicating AOD-9604’s effect is indeed mediated through that fat-burning receptor pathway​. These findings provided proof-of-concept that the HGH fragment could selectively trigger lipolysis in vivo.
• Initial Human Trial (12-Week): A randomized clinical trial in humans gave promising, though modest, results. Over 12 weeks, obese subjects who received AOD-9604 (at a dose of 1 mg daily) lost on average 2.6 kg of body weight, compared to about 0.8 kg in the placebo group. In other words, the AOD-9604 group lost roughly 1.8 kg more than those on placebo, suggesting a measurable fat-reduction effect. Interestingly, this trial found that higher doses did not produce greater weight loss – for instance, a 10 mg/day dose led to a smaller average weight reduction than the 1 mg dose. This lack of a dose-response implied there might be an optimal low dose for AOD-9604’s efficacy.
• Extended Human Trial (24-Week): To truly assess AOD-9604’s potential as an obesity treatment, a larger and longer trial was conducted. This 24-week study enrolled 536 obese individuals and tested daily AOD-9604 against placebo. The outcome was disappointing: by the end of the trial, AOD-9604 did not show a statistically significant weight loss advantage over placebo​. While there were slight reductions in weight, the difference was too small and inconsistent to deem the peptide effective for obesity on its own. As a result, in 2007 the development of AOD-9604 as a standalone anti-obesity drug was halted​. In the eyes of regulators and the sponsoring company, the peptide’s benefits didn’t justify it becoming a prescription weight loss medication.
• Safety and Tolerability: Across all clinical studies, totaling over 900 participants, AOD-9604 displayed an excellent safety profile. Research reports found no significant adverse effects attributable to the peptide​. Vital signs, blood markers, and metabolic parameters remained normal. Importantly, AOD-9604 caused no deleterious changes in blood sugar, insulin levels, or IGF-1, confirming that it stays true to its selective action. A 2013 safety study concluded the peptide was well-tolerated at various doses, with no difference in side effects between AOD-9604 and placebo groups. Additionally, patients did not develop antibodies against AOD-9604, which means the peptide did not trigger an immune reaction even with repeated dosing​. Overall, from a safety standpoint, AOD-9604 behaved more like a benign fragment than a powerful hormone – a reassuring sign for research use.

In summary, AOD-9604’s research results show a peptide that is safe and does exert a fat-reducing effect, but one that is relatively modest when used alone in humans. In animal and cell models, it clearly enhances lipolysis. In humans, it can lead to a bit more fat loss than placebo, but not to a dramatic degree by itself. These outcomes have guided scientists to think of AOD-9604 not as a cure-all, but as one potential component in a multi-faceted approach to studying and managing obesity. (For example, pairing AOD-9604 with other metabolic interventions could yield synergistic effects – a concept we’ll explore next.)

(External research note: One smaller study even hinted at metabolic benefits beyond weight loss – in people with impaired glucose tolerance, AOD-9604 therapy was associated with a lower progression rate to diabetes than placebo. While preliminary, this suggests the peptide’s effects on fat might improve overall metabolic health.)

Comparison to Other Peptides (GLP-1 Sema and MOTS-c)

In the realm of weight loss and metabolism research, AOD-9604 is not alone. Several other peptides have gained prominence for their effects on body weight. Notably, GLP-1 Sema and MOTS-c are two compounds often discussed alongside AOD-9604, each with very different modes of action. Understanding how AOD-9604 compares to these can help researchers choose the right tool or combination for their studies.

AOD-9604 vs. GLP-1 Sema

GLP-1 Sema is a peptide drug that has made headlines as a breakthrough in obesity treatment. It is a GLP-1 receptor agonist, meaning it mimics a gut hormone (GLP-1) that regulates insulin and appetite​. Clinically, GLP-1 Sema (branded as Wegovy® for weight loss, originally developed for type 2 diabetes as Ozempic®) has shown remarkable efficacy in helping patients lose weight by reducing hunger and calorie intake. How does it work? GLP-1 Sema activates GLP-1 receptors in the brain and digestive system, leading to enhanced feelings of fullness, reduced appetite, and slower gastric emptying​. Essentially, it helps people eat less and feel satisfied longer. It also improves insulin release and blood sugar control, which can indirectly support fat loss.

By contrast, AOD-9604 works peripherally on fat tissue rather than centrally on the brain. AOD-9604 does not suppress appetite or food intake – so if a subject overeats, AOD-9604 alone won’t prevent weight gain. Instead, AOD-9604’s strength is in prompting the body to burn existing fat stores more readily​. One could say GLP-1 Sema addresses the “calories in” side of the equation, while AOD-9604 addresses the “calories out” (energy expenditure) side. GLP-1 Sema’s dramatic results in clinical trials (patients losing 10-15% of body weight in a year) outperform what AOD-9604 alone achieved. However, GLP-1 Sema is a full prescription drug with systemic effects, whereas AOD-9604 is a gentler research peptide.

For researchers, combining insights from both can be valuable. In fact, there is interest in whether adding a lipolytic agent like AOD-9604 could enhance the fat-loss achieved by GLP-1 analogs like GLP-1 Sema. Each attacks obesity from a different angle: one by cutting down appetite, the other by ramping up fat utilization. It’s worth noting that GLP-1 Sema is FDA-approved for weight loss (in specific doses), reflecting its proven efficacy, whereas AOD-9604 remains research-only. Nonetheless, AOD-9604’s selective action can make it a useful adjunct in experimental settings.

AOD-9604 vs. MOTS-c

MOTS-c is another intriguing peptide in the weight management toolkit, though it operates very differently from both AOD-9604 and GLP-1 Sema. MOTS-c is a short peptide (16 amino acids) encoded by the mitochondria (the energy powerhouses of cells). Its primary role is in regulating metabolic functions, especially how cells utilize glucose and fats for energy. Research has shown that MOTS-c can enhance glucose metabolism and insulin sensitivity. For example, in mice fed a high-fat diet, MOTS-c treatment improved insulin resistance and helped prevent obesity from developing​. This peptide essentially makes the body’s cells (particularly muscle cells) more efficient at burning fuel and less prone to storing excess calories as fat.

Comparing MOTS-c to AOD-9604:

• AOD-9604 acts directly on fat cells to induce lipolysis (fat breakdown). It’s somewhat like hitting the “release fat” button.
• MOTS-c, on the other hand, acts on a more systemic level to improve overall metabolic performance. It can increase the number of calories burned by making metabolism more efficient and can reduce the tendency to gain fat by improving insulin action.

Notably, MOTS-c might not cause immediate fat breakdown like AOD-9604, but it creates an environment where fat is less likely to accumulate. It’s also been associated with increased exercise capacity and muscle energy usage in research studies. Because of these differences, MOTS-c and AOD-9604 could be seen as complementary. One targets the fat tissue specifically, while the other targets muscle and overall metabolic pathways. For researchers, a combination of MOTS-c + AOD-9604 is interesting for studying synergistic effects on weight loss: AOD-9604 frees fatty acids from adipose tissue, and MOTS-c helps muscles and other tissues burn those fatty acids more effectively.
In practical terms, these comparisons highlight that no single peptide covers all bases when it comes to weight loss:

• AOD-9604 = focuses on fat breakdown.
• GLP-1 Sema = focuses on appetite and caloric intake.
• MOTS-c = focuses on metabolic efficiency and insulin action.

Understanding each peptide’s strengths allows scientists to design better research protocols. In some cases, combining them might offer a more comprehensive approach. (Indeed, Spartan Peptides offers a “Skinny & Fit Stack” product that includes AOD-9604 + GLP-1 Sema + MOTS-c, reflecting this multi-angle strategy – more on this below.)

Usage and administration in research

Looking at the various studies on AOD 9604, its administration included four different routes in lab models.

Oral

The most common route used for weight loss was oral. In the studies on rats, the dose included 500 microg/kg over 19 days, showing a 50% reduction in weight gain.

Researchers administered six doses for human obesity research: 0, 1, 5, 10, 20, and 30 mg. The 1 mg dose delivered the most significant results for fat loss over 12 weeks.

Researchers administered three different oral doses in the safety, tolerability, and pharmacodynamics assessment. Participants received increasing doses of AOD 9604 and placebo ranges of 9, 27, and 54 mg.

Intra-articular injections

The study on white rabbits to determine AOD 9604 for cartilage regeneration in osteoarthritis involved intra-articular injections to the knee. It occurred in four groups.

The first and second groups didn’t receive any measure of AOD 9604. The third group received 0.25 mg and the fourth group received the same, along with 6 mg of hyaluronic acid (HA).

IV infusion

In the safety, tolerability, and pharmacodynamics assessment, two different dose-escalating studies occurred. In the first, 15 males received three single dosages of AOD 9604 ranging from 25 to 400 µg/kg bodyweight.

The second study involved 23 obese subjects. Each participant received four single dosages of AOD 9604 via IV infusion. One was a placebo and the others measured at 25, 50, and 100 µg/kg.

Intranasal

The study to determine if LAT8881 could aid in treating IAV infections involved daily intranasal dosing on mice. Researchers administered doses of 5, 10, and 20 mg kg-1 one day postinfection. It didn’t observe any weight loss.

Side effects and safety considerations

During the safety, tolerability, and pharmacodynamics assessment, researchers didn’t discover any serious adverse events (SAE).

AOD 9604 didn’t produce any of the negative effects associated with other weight loss drugs, like HGH. There were no growth promoting or pro-diabetic effects, cancer, edema, hypertension, or induction of insulin resistance and glucose intolerance.

AOD 9604’s safety and tolerability profile result was excellent and indistinguishable from the placebo. This assessment monitored its usage within 24 hours to a week and over 14 weeks.

Who can benefit from AOD 9604 research?

AOD 9604 isn’t effective enough at treating obesity, but it still offers weight loss benefits. Several companies realized this and started exploring its potential applications.

This peptide’s effects on fat cells makes it ideal for targeting cellulite and subcutaneous fat. By delivering it transdermally (through the skin) it may be able to effectively combat these fatty areas.

Cosmeceutical applications for AOD 9604 could also prove advantageous for health and wellness enthusiasts. They may experience the following benefits:

• Enhanced athletic performance: Less body fat can improve athletic performance. Fitness enthusiasts could experience more muscle definition, which can contribute to agility, strength, endurance, and speed.
• Better mental health: Reducing subcutaneous fat and cellulite can improve aesthetics, leading to higher self-esteem.
• Improved health indicators: Excessive subcutaneous fat can influence negative health outcomes. Decreasing it can lead to more balanced cholesterol and blood pressure levels and improve blood sugar control and metabolic health.

AOD 9604’s ability to stimulate lipolysis while inhibiting lipogenesis suggests a need for further research as a weight management therapy. It could benefit people experiencing increased body fat due to age or metabolic dysfunctions.

This peptide also presents potential as a treatment for diabetes. Participants with impaired glucose tolerance who used it showed a reduction in their likelihood of developing diabetes.

Combining AOD 9604 with other peptides, like GLP-1 Sema, ipamorelin, or CJC-1295, could make them more effective for weight loss. It might be able to regulate the insulin-boosting effect in people without type 2 diabetes.

Integrating AOD 9604 into experimental protocols

We can gain various insights into metabolism, fat loss, and growth hormone (GH) pathways by incorporating AOD 9604 into broader research initiatives. Here’s how:

Complementary research areas

Understanding how AOD 9604 influences fat loss mechanisms without negatively affecting insulin sensitivity could make it helpful in research on fat metabolism pathways. This property also makes it easier for researchers to study its GH-related pathways.

Its lack of impact on IGF-1 levels also suggests its potential to help us understand metabolic dysregulation.

Holistic research approach

Research on combining AOD 9604 with other peptides could lead to synergistic effects.

Developing protocols to evaluate combining it with pharmacological agents or diet and exercise may provide a better understanding of weight management strategies.

Burn fat with Spartan Peptides

AOD 9604 has the potential to help you burn fat and manage your weight more effectively. It plays a crucial role in fat metabolism research.

It also has potential as an agent in peptide therapy because it presents few adverse effects. Despite its short-term safety in trials, the FDA has yet to approve it for anything outside R&D.

Contact us today if you want to learn more about AOD 9604’s alternate applications.

Frequently asked questions

Is AOD 9604 approved for human use?

Yes, the FDA has approved AOD 9604 for R&D in humans.

Can AOD 9604 be used for muscle building in research?

No, but it could boost the effectiveness of other muscle-building peptides like tesamorelin because it reduces fat and prevents weight gain.

How long do studies take to show effects of AOD 9604?

Studies showed an average of 2.8 kg (6.1 lbs) weight loss over 12 weeks.

Does AOD 9604 affect appetite in research models?

Very rarely. It doesn’t suppress appetite, but could increase it.

What are the main R&D applications for AOD 9604?
AOD 9604 has R&D applications that include fat loss and weight management.

Disclaimer

The FDA has only approved AOD 9604 for research, not medical or therapeutic use. If you want to pursue a deeper understanding of how it works or explore its potential benefits, exercise caution.

It’s crucial to conduct any research in a safe and healthy manner. Consult a professional researcher or physician before using AOD 9604.